Who Supplies Plasma to India from SWITZERLAND

To import finished pharmaceutical formulations containing plasma into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This involves registering the manufacturing premises and the specific drug products. The registration process includes submitting a Drug Master File (DMF), Good Manufacturing Practice (GMP) certificates, and a Certificate of Pharmaceutical Product (COPP). The application is submitted to the Drugs Controller General of India (DCGI) and typically takes up to nine months for approval.

Once registered, an Import License (Form 10) is required for each shipment. This license is valid for three years and must be renewed before expiration.

For plasma formulations under HS Code 30029010, the import license and registration are mandatory.

Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories. This includes batch-wise testing, where three consecutive batches are tested for quality, safety, and efficacy. The manufacturer must provide a Certificate of Analysis (CoA) from the exporting country’s laboratory, along with stability data demonstrating compliance with ICH Zone IV guidelines.

Port inspection by customs drug inspectors is mandatory to ensure compliance with Indian standards.

In April 2025, the Indian government mandated that all imported drugs, including finished formulations containing plasma, must have an Import Registration Certificate and Import License from CDSCO. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market.

The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may impact the import of finished formulations. However, specific details regarding its effect on plasma formulation imports from Switzerland are currently unavailable.

India imports finished plasma formulations to meet the demand for specialized treatments not available domestically. These include patented or branded formulations and specific dosage forms. The domestic capacity for such specialized plasma formulations is limited, leading to a reliance on imports.

The market size for plasma formulations in India is substantial, with a total export market of $2.8 million across 215 exporters to 90 countries.

The Basic Customs Duty (BCD) for plasma formulations under HS Code 30029010 is 10%.

An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable, totaling 3%.

The Integrated Goods and Services Tax (IGST) is 0% for this category.

There are no additional duties such as Countervailing Duty (CVD) or National Calamity Contingent Duty (NCCD).

The total landed duty is approximately 10.3%.

India sources plasma formulations from Switzerland due to the country's strong reputation for high-quality pharmaceutical products, adherence to international GMP standards, and the availability of specialized formulations not produced domestically.

Other suppliers include China, Germany, and the United States.

Switzerland holds a significant share in the Indian market for plasma formulations, attributed to its competitive advantages in quality and innovation.

India imports plasma formulations from Switzerland due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations not produced domestically.

Swiss manufacturers offer patented formulations and specific dosage forms that meet the therapeutic needs of the Indian market.

The quality assurance and regulatory compliance of Swiss products make them a preferred choice for Indian importers.

Compared to China, Germany, and the United States, Switzerland offers higher quality standards, innovative formulations, and reliable supply chains.

While other countries may offer lower prices, Swiss products are often preferred for their superior quality and compliance with international standards.

Switzerland's unique advantage lies in its ability to provide specialized plasma formulations that meet specific therapeutic requirements.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions.

There have been no significant shortages reported in the past year.

To mitigate risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, and maintain robust quality assurance processes.

1. 1Diversify sourcing by engaging multiple suppliers to reduce dependency on a single source.
2. 2Implement comprehensive inventory planning to manage supply chain disruptions effectively.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Establish minimum order quantities (MOQs) that align with demand forecasts to optimize inventory levels.
5. 5Conduct thorough supplier qualification processes, including audits and assessments, to ensure compliance with quality and regulatory standards.

1. 1Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the manufacturing premises with CDSCO.
3. 3Register the specific drug formulations with CDSCO.
4. 4Obtain a Drug Import License (Form 10) from CDSCO.
5. 5Secure a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
6. 6Engage a customs broker for clearance procedures.